Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/90.BMDkfsfZ.js ...

A recent study has revealed a strong link between insulin resistance and an increased risk of aortic stenosis (AS), a ...

Anteris Technologies Global Corp. aims to raise $75 million in an IPO for aortic stenosis treatment development in a growing ...

A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development ...

Edwards Lifesciences Corporation (NYSE: EW) will discuss the company’s focused strategy for long-term sustainable growth, ...

Edwards Lifesciences (NYSE:EW) today announced its plans for significant growth as a purely structural heart company in 2025.

Abbott Announces First Step Toward Its Software-Guided Balloon-Expandable TAVI System to Treat Aortic Stenosis • The investigational transcatheter aortic valve implantation (TAVI) system will ...

FY24 consensus $5.83B. “It is an exciting day for Edwards as we share our vision for 2025 and how our talented team and focus in structural ...

A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world's most common heart valve disease -- aortic stenosis (AS).

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

In the CONDUCT-TAVI study, the use of a self-expanding valve was not associated with an increased risk of pacemaker.